Influenza virus and avian influenza
DOI:
https://doi.org/10.51481/amc.v50i1.346Keywords:
Influenza A, avian influenza, pandemia, H5N1Abstract
This article presents a review of Influenza virus, its biology, its mechanism of antigenic variation and its prevention by vaccination and the use of antivirals. The pandemics produced by this virus through history are presented. The appearance of the avian flu virus H5N1 is analyzed and its pathogenesis and strategies of prevention are discussed. National and international information about pandemic preparedness is presented.
Downloads
References
Webster RG. Influenza: An Emerging Disease. Emerg Infect Dis 1998;4:1-7.
Murphy BR & Webster RG.. Orthomyxovirus. En: Virology. Fields BN et al (ed). Lippincott-Raven Publishers. 1996. pp.1397-1445
Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF Williams C.S. Grenfell B.T. Host species barriers to Influenza Virus Infections. Science 2006; 312:4-13.
Yamada Sh, Suzuki Y, Suzuqui T, Le M, Nidom ch, Sakai Y, et al. Haemagglutinin mutations responsable for the binding of H5N1 influenza A virases to human-type receptors. Nature. 2006; 444:378382.
Webster R. G. Peiris M, Chen H, Guan Y. H5N1 Outbreaks and Enzootic Influenza Emerg Infect Dis 2006;12:3-8.
Palese P. Making Better Influenza Virus Vaccines? Emerg Infect Dis 2006; 12:61-64.
Taubenberger JK & Morens, DM. 1918 Influenza: the Mother of All Pandemics. Emerg Infect Dis 2006; 12: 1-12.
Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 ""Spanish"" influenza pandemic. Bull Hist Med 2002; 76:105-15
Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, et al. Enhanced virulence of Influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004; 431:703-701.
Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origen and evolution of the 1918 ""Spanish"" influenza virus hemagglutinin gene. Proc Nalt Acad Sci USA 1999; 96:1651-56.
Kilbourne ED. Influenza Pandemics of the 20th Century. Emerg Infect Dis. 2006;12:9-14
Dowdle WR. Influenza Pandemic Periodicity, Virus Recycling and the Art of Risk Assessment. Emerg Infect Dis 2006;12:34-39.
Karasin AI, Olsen CW, Anderson GA. Genetic characterization of an H1N2 influenza virus isolated from a pig in Indiana. J Clin Microbiol. 2000;38:2453-6.
Yeun KY, Wong SSY. Human Infection by avian influenza A H5N1. Hong Kong Med J. 2005;11:189-199.
Liu J, Xiao H, Lei F, Zhu Q, Qin K, Zang X-W et al. Highly Pathogenic H5N1! Influenza Virus Infection in Migratory Birds. 2005; Science 309:1206.
Webster R G. Wet markets- continuing source of severe acute respiratory syndrome and Influenza? Lancet. 2004;363:234
Halvorson S. Avian Influenza. Disponible en: www.cvm.umn.edu/ai_ old/home.html
Luke CJ & Subbaroa K. Vaccines for Pandemic Influenza. Emerg Infect Dis 2006; 12:66-72.
Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R et al. Avian H5N1 influenza in cats. Science 2004;306: 241.
Shinyal K, Ebina M, Yamada Sh, Ono M, Kasai N, Kawaoka Y, et al. Avian flu: Influenza virus receptors in the human airway. Nature 2006; 440: 435.
Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME, Fouchier RAM. Global Patterns of Influenza A virus in Wild Birds. Science. 2006; 312:4-8.
Garcia-Sastre A. Antiviral Response in Pandemic Influenza Viruses. Emerg Infect Dis 2006;12:44-7.
Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-Mediated Protection in Influenza Infection. Emerg Infect Dis. 2006;12:48-54.
Quirk M. H5N1 genes show avian origins and drifting. Emerg Infect Dis 2005; 11: 1510-21.
Stephenson I, Bugarini R. Nicholson KG, Podda a, Wood JM Zambon MC, Katz JM. Cross-Reactivity to highly Pathogenic Avian Influenza
H5N1 Viruses after Vaccination with Nonadjuvant and MF59Adjuvantes Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy. JID 2005;191:1210-5
Yang ZY, Wei ChJ, Kong WP, Wu L, Xu L Smith D.F. Nabel GJ. Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity. Science 2007; 317:825-8.
Taubenberger JK, Reid A.H. & Fanning TG. Capturing a Killer Flu virus. Scientific American. 2005. pp. 62-71.
Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis. 2006; 6:458-9.
Influenza pandemic preparation—much still to be done. Lancet Infect Dis 2006; 6: 315.
Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458-9.
Gani, R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential Impact of Antiviral Drug Use during Influenza Pandemic. Emerging Infectious Diseases 2006; 11:1-13.
Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of antiH5 antibody among household and social contacts. J Infect Dis 1999;180:1763-70.
Buxton Briges C, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis. 2000;181:344-8.
Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002,8:950-4.
Cheung CY, Poon LL, Lau AS, Shortridge KF, Gordon S, Guan Y, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360:1831-7.
Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza type A subtype H5N1 disease. Lancet 2004; 363:617-9.
Bonn D. Wild birds, poultry, and avian influenza. Lancet Infect Dis 2006;6:262
Secretaría de Salud. Acciones Básicas ante una Pandemia de Influenza. Boletín de Práctica Médica Efectiva. Diciembre 2006.
Yang Y, Halloran ME, Sugimoto J, Longini, Jr IM. Detecting human-to-human transmission of avian influenza A (H5N1). Disponible en: http://www.cdc.gov/EID/content/13/9/1348.htm>
Herrero, L. Alfaro, W. Virus Influenza circulantes en Costa Rica 1998 - 2001. ¿Cuándo vacunar? Acta Médica Pediátrica 16(3):111115,2002.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
